Business Context and Reporting Period
Company: Boston Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2007
Overview: Boston Scientific is a global developer and manufacturer of medical devices. The reporting period includes the full nine-month results of the Cardiac Rhythm Management (CRM) and Cardiac Surgery businesses acquired from Guidant Corporation in April 2006. The company is currently executing strategic initiatives to reduce expenses, divest non-strategic assets, and align costs with revenues.
Key Financial Metrics
| Metric (in millions) | Q3 2007 | Q3 2006 | 9 Months 2007 | 9 Months 2006 |
|---|---|---|---|---|
| Net Sales | $2,048 | $2,026 | $6,204 | $5,756 |
| Gross Profit | $1,473 | $1,396 | $4,498 | $4,075 |
| Gross Margin | 71.9% | 68.9% | 72.5% | 70.8% |
| Operating (Loss) Income | $(147) | $195 | $416 | $(3,233) |
| Net (Loss) Income | $(272) | $76 | $(37) | $(3,854) |
| Diluted EPS | $(0.18) | $0.05 | $(0.02) | $(3.19) |
| Cash from Operations (9M) | $626 | $1,480 | ||
| Free Cash Flow (9M) | ||||
| Total Debt (Gross) | $8,157 (as of Sept 30, 2007) | |||
| Cash & Equivalents | $1,237 (as of Sept 30, 2007) | |||
| Net Debt | $6,920 (as of Sept 30, 2007) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 1% in Q3 2007 and 8% for the first nine months of 2007 compared to the prior year. The nine-month increase is primarily due to the inclusion of a full period of CRM and Cardiac Surgery operations, offset by a significant decline in U.S. drug-eluting stent sales due to market contraction.
- Profitability: The company reported a net loss of $272 million in Q3 2007, compared to net income of $76 million in Q3 2006. This reversal was driven by acquisition- and divestiture-related charges of $435 million (after-tax), including a $352 million goodwill writedown related to the sale of the auditory and drug pump businesses.
- Operating Expenses: SG&A expenses increased 15% for the first nine months of 2007, largely due to the inclusion of full-period CRM and Cardiac Surgery costs. R&D expenses increased 13% for the same period.
- Debt Reduction: In Q3 2007, the company prepaid $1.0 billion on its senior term loan, reducing total debt from $8.902 billion at year-end 2006 to $8.157 billion at September 30, 2007.
Guidance, Outlook, and Risks
Strategic Initiatives and Restructuring
In October 2007, the Board approved a plan to eliminate approximately 2,300 positions worldwide. The company expects total pre-tax expenses of $450 million to $475 million associated with this plan, with $275 million to $300 million recorded in Q4 2007. The goal is to reduce annualized R&D and SG&A expenses by $475 million to $525 million by the end of 2008.
Divestitures
- Advanced Bionics: Agreed to sell the auditory business and drug pump program for $150 million (expected close Jan 2008).
- Cardiac & Vascular Surgery: Entered a definitive agreement to sell these businesses for approximately $750 million (expected close Q4 2007 or Q1 2008).
Market Outlook
- Coronary Stents: The worldwide market is estimated to decline to $5.0 billion in 2007 from $6.0 billion in 2006 due to concerns over late stent thrombosis. U.S. drug-eluting stent penetration dropped to 63% in Q3 2007 from 85% in Q3 2006. Boston Scientific remains the U.S. market leader with 56% share.
- CRM: Worldwide CRM sales increased 16% in Q3 2007. The company resolved an FDA warning letter regarding CRM facilities in April 2007, allowing for the resumption of new product launches.
Risks and Contingencies
- Legal Proceedings: Significant litigation exposure remains, particularly regarding Guidant-related product liability (defibrillators/pacemakers) and patent disputes with Johnson & Johnson and Medtronic. Legal accruals totaled $680 million as of September 30, 2007.
- Regulatory: The company received an FDA warning letter in August 2007 regarding clinical investigations for the TriVascular AAA program (terminated in 2006). A corporate warning letter from 2006 regarding quality systems is being addressed.
- Credit Ratings: Credit ratings were downgraded to non-investment grade (BB+ by S&P and Fitch; Ba1 by Moody's) in Q3 2007 with a negative outlook.
Key Facts for Investor Verification
- Restructuring Costs: Verify the timing and magnitude of the $450-$475 million restructuring charge, specifically the portion expected in Q4 2007.
- Divestiture Closings: Monitor the closing dates and final proceeds for the Advanced Bionics ($150M) and Cardiac/Vascular Surgery ($750M) sales.
- Stent Market Dynamics: Track the recovery of the U.S. drug-eluting stent market and the impact of new competitor entries on Boston Scientific's market share and pricing power.
- Debt Covenants: Confirm continued compliance with debt covenants, specifically the debt-to-EBITDA ratio (currently ~3.6x) and interest coverage ratio (~3.9x), given the non-investment grade credit rating.
- Legal Accruals: Assess potential increases in the $680 million legal accrual related to Guidant product liability and patent litigation.